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To the Editor: 
We enthusiastically support Mahmoudinezhad and colleagues in their article “COVID-19 Pandemic: Are 
We Back to Normal?” and wish to add our heightened concern for open-angle glaucoma (OAG) patients 
of African descent (AD). COVID-19 infection disproportionally affects the African American population 
with Johns Hopkins University and American Community Surveys reporting rates of infection and death 
3 times higher in majority Black counties when compared with majority White counties.1,2 Similar to 
COVID-19 infection, OAG also disproportionately affects persons of AD, who are on average 6 times 
more likely to be diagnosed with OAG, and experience earlier onset and increased severity compared 
with those of European decent (ED).3,4 The higher rates of both glaucoma and COVID-19 infection and 
their complications suggest the valid concerns of maintaining appropriate disease management outlined 
by Mahmoudinezhad and colleagues and novel approaches to maintain care are especially important for 
persons of AD. 
Elevated intraocular pressure (IOP) has long been identified as a strong contributor to glaucoma 
pathophysiology. However, many patients with OAG either do not exhibit elevated IOP or experience 
continued disease progression despite low or medically reduced IOP, thus highlighting the multifactorial 
nature of the disease. Low ocular perfusion and/or impaired ocular circulation have long been identified 
as contributory mechanisms of OAG5 and persons of AD are known to have considerably higher rates of 
cardiovascular diseases, with early onset and high levels of severity.6 In our laboratories, we previously 
identified how ocular vascular health may be a more significant contributing factor in OAG patients of 
AD compared with ED. Significantly, we found lower blood flow biomarkers in all retrobulbar blood 
vessels including those supplying the retina and optic nerve head in OAG patients of AD compared with 
ED.7 In addition, significantly larger reductions in retinal capillary and retrobulbar blood flow were 
identified and strongly correlated with OAG changes in optic nerve head structure and macular thickness 
over 4 years in OAG patients of AD compared with ED.8 Furthermore, we observed higher venous retinal 
oxygen values and lower arterial venous difference (an estimation of retinal capillary oxygen extraction) 
in OAG patients of AD compared with patients of ED with statistically similar IOP and OAG disease stage 
status.9 
Importantly, preliminary data suggests COVID-19 causes microvascular damage, inflammation, and 
thrombosis in various organs. Patients suffering from COVID-19 were found to have extensive 
endothelial injury and thrombi with microangiopathy throughout the lungs on autopsy.10,11 When 
compared with the autopsy of patients with influenza, patients with COVID-19 were 9 times more likely 
to have microthrombi present in the alveoli.10 Elevations of D-dimer and antiphospholipid antibodies 
support the proposed role of COVID-19 in the development of vascular disease and thrombogenesis.11 
The damage caused by COVID-19 to the microvasculature of various organs systems such as the lungs 
may explain the higher rates of disease complications and death among patients with underlying 
cardiovascular comorbidities.12 Insult to the microvasculature is thus a shared characteristic of both 
COVID-19 and glaucoma, and this mechanistic overlap highlights the urgent need to understand if 
COVID-19 elevates glaucoma risk in patients whose vascular health is compromised, especially in 
persons of AD. 
We strongly support the concerns for appropriate ophthalmic disease management discussed by 
Mahmoudinezhad and colleagues as COVID-19 represents an emerging and immediate threat to human 
welfare and medical resource allocations. The shared vascular pathologies and similar epidemiological 
disparities between COVID-19 infection and OAG is a significant concern to be explored. In view of this, 
we suggest for the first time that a COVID-19 infection with its known microvascular insult may elevate 
the risk for glaucoma onset and progression especially in high-risk patient groups with vascular 
comorbidities and encourage clinicians to be aware of the possible elevated risk in persons of AD 
infected by COVID-19. 
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